Nelson R&D/Lilly Azone agreements
Executive Summary
Nelson has reached two agreements with Lilly Internatl. covering the development of a cream formulation and a transdermal delivery patch for the overseas marketing of an unnamed compound. "The drug under development is already widely accepted as an oral product with 1983 worldwide sales of approximately $330 mil." and has been marketed worldwide for "more than a decade," Nelson said. The Irvine, Calif.-based research firm indicated that the same compound in Nelson delivery systems is being developed for another firm for domestic marketing.